Quinapril
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Quinapril: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Quinapril is an ACE inhibitor internationally used for essential hypertension and heart failure; it is not currently registered or marketed in South Africa (0 SAHPRA registrations). The TxGNN model predicts a possible link to Malignant Renovascular Hypertension, but this prediction is supported by 0 clinical trials and 0 publications, and the drug’s own rationale flags a known safety concern rather than a validated new-use hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from SAHPRA registry data (drug not marketed); internationally, quinapril (ACE inhibitor) is indicated for hypertension |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, quinapril belongs to the ACE inhibitor (ACEi) class, which lowers systemic blood pressure by suppressing the renin-angiotensin-aldosterone system (RAAS). Its efficacy in essential hypertension is well established internationally.
Mechanistically, the model’s link between quinapril and malignant renovascular hypertension is plausible on the surface — both involve severe elevation of blood pressure mediated by RAAS activity. However, malignant renovascular hypertension is frequently caused by bilateral (or solitary-kidney) renal artery stenosis. In this setting, ACE inhibition dilates the efferent glomerular arteriole and can cause an abrupt drop in glomerular filtration pressure, precipitating acute kidney injury. This is a recognized safety hazard requiring careful exclusion of renal artery stenosis, not a novel therapeutic opportunity — the high TxGNN score reflects embedding proximity between “ACE inhibitor” and “hypertension/renal” nodes in the knowledge graph rather than a validated efficacy signal.
No clinical trial or literature evidence currently exists to support (or further characterize the risk of) this specific use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: This evidence pack flags a Blocking-severity data gap — SAHPRA label warnings/contraindications for quinapril are not yet available, which prevents a full initial safety assessment (S1 stage) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Quinapril is not currently marketed or registered in South Africa (0 SAHPRA licenses), and label-level safety data (warnings/contraindications) is unavailable — a blocking gap for initial safety review.
- There is no clinical trial or published literature evidence for use in malignant renovascular hypertension, and the underlying mechanistic rationale itself identifies a known ACE-inhibitor safety hazard (risk of acute kidney injury in renal artery stenosis) rather than a novel efficacy signal.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI) / label warnings and contraindications for quinapril
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
- Any preclinical or case-level evidence specifically addressing quinapril use in confirmed vs. excluded renal artery stenosis
- A formal safety opinion before this candidate can advance past S1
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.